| Title |
Author |
Type |
Date |
Words |
| I-MAB announces presentation on uliledlimab at ASCO 2021 meeting. |
|
|
Apr 14, 2021 |
209 |
| OncoCyte presents new data on potential for pan-cancer utility of DetermaIO. |
|
|
Apr 11, 2021 |
284 |
| Roche's Tecentriq receives positive CHMP opinion as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer. |
|
|
Mar 29, 2021 |
252 |
| Roche's Tecentriq receives positive CHMP opinion as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer. |
|
|
Mar 29, 2021 |
251 |
| I-Mab Touts Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the US. |
|
|
Feb 8, 2021 |
453 |
| Clinical characteristics and outcomes for young patients with advanced urothelial carcinoma. |
Chehroudi, All Cyrus; Lavoie, Jean-Michel; Black, Peter C.; Eigl, Bernhard J. |
Report |
Feb 1, 2021 |
2356 |
| Japan's Drug Regulation Framework: Aiming for Better Health or Bigger Profits? |
Ozaki, Akihiko; Senoo, Yuki; Saito, Hiroaki; Crump, Andy; Tanimoto, Tetsuya |
|
Jan 1, 2021 |
1283 |
| Roche Secures European Approval For Tecentriq As Liver Cancer Drug. |
|
|
Nov 2, 2020 |
192 |
| Corvus Pharmaceuticals reports Q3 EPS (33c), consensus (24c). |
|
Financial report |
Oct 29, 2020 |
285 |
| Exelixis announces 1st patient enrolled trial cohort evaluating XL092 in combo. |
|
|
Oct 26, 2020 |
185 |
| NeoImmuneTech Forges a Second Clinical Collaboration with Roche to Evaluate NT-I7 (efineptakin alfa) in Combination with PD-L1 Checkpoint Inhibitor in First-line Non-small Cell Lung Cancer. |
|
|
Oct 22, 2020 |
318 |
| Exelixis to Present the Preclinical Profile and Initial Clinical Pharmacokinetics of Oral Tyrosine Kinase Inhibitor. |
|
|
Oct 12, 2020 |
484 |
| Exelixis announces new XL092 data at ENA Symposium. |
|
|
Oct 9, 2020 |
344 |
| FDA approves triple-drug combination for melanoma. |
Mulcahy, Nick |
|
Oct 1, 2020 |
248 |
| Exelixis announces results from two cohorts of COSMIC-021 trial. |
|
Financial report |
Sep 21, 2020 |
213 |
| Pieris presents data from monotherapy, atezolizumab combo studies of PRS-343. |
|
|
Sep 20, 2020 |
537 |
| Cancer patient first to receive new treatment. |
ANNA TWIZELL anna.twizell@reachplc.com @annatwizell |
|
Sep 18, 2020 |
470 |
| The Current Strategies for Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer: The Place of Immunotherapy in Future. |
Ercelep, Ozlem |
|
Sep 1, 2020 |
2358 |
| Development of an Immune-Related Risk Signature in Patients with Bladder Urothelial Carcinoma. |
Jiang, Yaofei; Wang, Yibing; Li, Cong; Zou, Zhenhong; Liang, Bo |
Report |
Aug 31, 2020 |
4859 |
| KAHR wins FDA clearance to initiate Phase I/II clinical trial of DSP107 for treating solid tumors. |
|
|
Aug 13, 2020 |
216 |
| KAHR wins FDA clearance to initiate Phase I/II clinical trial of DSP107 for treating solid tumors. |
|
|
Aug 13, 2020 |
212 |
| FDA Approves Genentech's Tecentriq plus Cotellic and Zelboraf for People with Advanced Melanoma. |
|
|
Aug 3, 2020 |
749 |
| Shorts. |
Klotter, Jule |
|
Aug 1, 2020 |
1918 |
| Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis. |
Liu, Haoran; Ye, Tao; Yang, Xiaoqi; Lv, Peng; Wu, Xiaoliang; Zhou, Hui; Lu, Hongyan; Tang, Kun; Ye, |
|
Jul 31, 2020 |
14681 |
| Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer. |
Inoue, Akira |
|
Jul 1, 2020 |
4156 |
| Molecular Targeted Cancer Therapies and the Kidney. |
Aksu, Ozge Bas; Sadioglu, Rezzan Eren; Sengul, Sule |
|
Jul 1, 2020 |
6275 |
| The expanding role of biomarker testing in non-small cell lung cancer. |
Vennapusa, Bharathi |
|
Jul 1, 2020 |
1948 |
| Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment. |
Roviello, Giandomenico; Casadei-Gardini, Andrea; Nobili, Stefania; Mini, Enrico; Fancelli, Sara |
|
Jun 30, 2020 |
2525 |
| Identification of PDLl-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors. |
Wu, Yanping; Lin, Lianjun; Liu, Xinmin |
|
Jun 30, 2020 |
5697 |
| Profiles of Immune Infiltration and Prognostic Immunoscore in Lung Adenocarcinoma. |
Li, Yanyan; Tao, Liping; Cai, Weiyang |
|
Jun 30, 2020 |
9865 |
| Promising signs in trials for personalised cancer vaccines. |
|
|
Jun 23, 2020 |
199 |
| Roche's Tecentriq in combination with Avastin gains FDA approval for most common liver cancer. |
|
|
Jun 3, 2020 |
225 |
| Roche's Tecentriq in combination with Avastin gains FDA approval for most common liver cancer. |
|
|
Jun 3, 2020 |
229 |
| Roche's Tecentriq Approved In US For Most Common Form Of Liver Cancer. |
|
|
Jun 2, 2020 |
346 |
| LONDON BRIEFING: Tesco's Finance Boss Alan Stewart To Retire. |
|
|
Jun 2, 2020 |
1674 |
| GLOBAL TOP NEWS SUMMARY: European Stocks Shrug Off US Unrest. |
|
|
Jun 2, 2020 |
1824 |
| The Cancer Immunotherapy Biomarker Testing Landscape. |
Walk, Eric E.; Yohe, Sophia L.; Beckman, Amy; Schade, Andrew; Zutter, Mary M.; Pfeifer, John; Berry, |
|
Jun 1, 2020 |
16518 |
| An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient. |
Krukowska, Kinga; Kieszko, Robert; Kurek, Katarzyna; Chmielewska, Izabela; Krawczyk, Pawel; Milanows |
|
May 31, 2020 |
2517 |
| Pulmonary Complications Secondary to Immune Checkpoint Inhibitors. |
Ahmad Hasan Albitar, Hasan; Duma, Narjust; Leventakos, Konstantinos; De Moraes, Alice Gallo |
|
May 31, 2020 |
3226 |
| The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis. |
Nie, Run-Cong; Zhao, Chong-Bang; Xia, Xiao-Wei; Luo, Ying-Shan; Wu, Ting; Zhou, Zhi-Wei; Yuan, Shu-Q |
Report |
May 31, 2020 |
6865 |
| Gossamer Bio announces presentation of KEYNOTE-A36 Phase 1/2 study data at ASCO. |
|
|
May 29, 2020 |
276 |
| Deep and Prolonged Response to Aurora A Kinase Inhibitor and Subsequently to Nivolumab in MYCL1-Driven Small-Cell Lung Cancer: Case Report and Literature Review. |
Kolla, Bhaskar C.; Racila, Emilian; Patel, Manish R. |
|
Apr 30, 2020 |
3663 |
| Metastatic Small-Cell Lung Cancer Presenting as Primary Adrenal Insufficiency. |
Esperti, Shawn; Stoelting, Austen; Scibelli, Nicolina; Moccia, David; Patel, Dveet; Haughton, Michae |
|
Mar 31, 2020 |
2035 |
| Advanced Lung Adenocarcinoma Patient with ERBB2 Amplification Identified by Comprehensive Genomic Profiling Benefits from Trastuzumab. |
Tao, Chi-Wei; Chen, Mei-Yin; Tseng, Ching-Min; Lapke, Nina; Chen, Shu-Jen; Tan, Kien Thiam |
Report |
Mar 31, 2020 |
2823 |
| Synlogic provides business, clinical update amid COVID-19 pandemic. |
|
|
Mar 30, 2020 |
412 |
| Identification of Prognostic Immune Genes in Bladder Urothelial Carcinoma. |
Su, Qisheng; Sun, Yan; Zhang, Zunni; Yang, Zheng; Qiu, Yuling; Li, Xiaohong; Mo, Wuning |
|
Mar 1, 2020 |
4600 |
| FDA Grants Priority Review to Genentech's Tecentriq Monotherapy as First-line Treatment of Certain People with Advanced Non-small Cell Lung Cancer. |
|
|
Feb 24, 2020 |
527 |
| FDA Grants Priority Review to Genentech's Tecentriq Monotherapy as First-line Treatment of Certain People with Advanced Non-small Cell Lung Cancer. |
|
|
Feb 20, 2020 |
527 |
| Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large, Canadian, multi-institutional database. |
Oake, Justin D.; Patel, Premal; Lavallee, Luke T.; Lattouf, Jean-Baptiste; Saarela, Olli; Klotz, Lau |
|
Feb 1, 2020 |
4689 |
| Genentech's Phase III Study of Tecentriq in People with Muscle-invasive Urothelial Cancer Fails to Meet Primary Endpoint. |
|
|
Jan 27, 2020 |
410 |
| Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer. |
|
|
Jan 24, 2020 |
1191 |
| European Commission approves Roche's Polivy for people with previously treated aggressive lymphoma. |
|
|
Jan 21, 2020 |
1589 |
| AI Therapeutics Creates AI-Driven Drug Development Platform. |
|
|
Jan 21, 2020 |
366 |
| Overexpression of an Immune Checkpoint (CD155) in Breast Cancer Associated with Prognostic Significance and Exhausted Tumor-Infiltrating Lymphocytes: A Cohort Study. |
Li, Yu-Chen; Zhou, Quan; Song, Qing-Kun; Wang, Rui-Bin; Lyu, Shuzhen; Guan, Xiudong; Zhao, Yan-Jie; |
Report |
Jan 1, 2020 |
4948 |
| Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries. |
Cembrola, Biancamaria; Ruzza, Valentino; Troise, Fulvia; Esposito, Maria Luisa; Sasso, Emanuele; Caf |
|
Jan 1, 2020 |
15860 |
| Safety and Efficacy in Relapsed or Refractory Classic Hodgkin's Lymphoma Treated with PD-1 Inhibitors: A Meta-Analysis of 9 Prospective Clinical Trials. |
Zhang, Xueyan; Chen, Li; Zhao, Yawei; Yin, Huiru; Ma, He; He, Miao |
|
Dec 31, 2019 |
9556 |
| Clinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients. |
Imoto, Koji; Kohjima, Motoyuki; Hioki, Tomonobu; Kurashige, Tomoyuki; Kurokawa, Miho; Tashiro, Shige |
|
Dec 31, 2019 |
7227 |
| Overweight, Obese People More Likely To Survive Cancer. |
Darwin Malicdem |
|
Dec 31, 2019 |
380 |
| An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors. |
Baseri, Babak; Samra, Bachar; Tam, Eric; Chiu, Edwin; Leaf, Andrea |
|
Dec 31, 2019 |
4860 |
| Skeletal Muscle Metastasis to Vastus Lateralis from a Urothelial Carcinoma: A Case Report and Review of Its Diagnosis and Management. |
Mainwaring, A.M.; Wells, H.; Banks, T.; Ellul, T.; Bose, P. |
|
Dec 31, 2019 |
2832 |
| Obesity May Boost Effectiveness of a Lung Cancer Therapy. |
|
|
Dec 30, 2019 |
490 |
| Study suggests high BMI may improve cancer survival. |
ANI |
Report |
Dec 29, 2019 |
477 |
| Cancer drug better for fatter patients; Scientists term it 'obesity paradox'. |
LUCY THORNTON |
|
Dec 27, 2019 |
115 |
| BMI, Survival Linked in NSCLC Treated With Atezolizumab; Overall, progression-free survival improved for patients with high BMI; link strongest with high PD-L1 expression. |
|
|
Dec 27, 2019 |
268 |
| Exelixis signs collaboration agreement with Roche. |
|
|
Dec 23, 2019 |
148 |
| Exelixis signs collaboration agreement with Roche. |
|
|
Dec 23, 2019 |
144 |
| Genentech meets primary endpoint in Phase III IMspire150 study of BRAF V600 mutation-positive advanced melanoma. |
|
|
Dec 17, 2019 |
164 |
| Genentech meets primary endpoint in Phase III IMspire150 study of BRAF V600 mutation-positive advanced melanoma. |
|
|
Dec 17, 2019 |
160 |
| Roche announces positive Phase III study results for Tecentriq plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma. |
|
|
Dec 13, 2019 |
1275 |
| Global Monoclonal Antibodies (MAbS) Market Report 2020 with Profiles of Johnson & Johnson, Merck, AbbVie, Amgen, Glaxosmithkline. |
|
Report |
Dec 11, 2019 |
982 |
| First Patient Dosed with Third ImmTAC Bispecific. |
|
|
Dec 9, 2019 |
226 |
| FDA approves Roche's Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer. |
|
|
Dec 4, 2019 |
1548 |
| What the Oncologist Needs From the Pathologist for Immune Therapies. |
Bernicker, Eric H. |
|
Dec 1, 2019 |
3001 |
| Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. |
Carbone, Carmine; Piro, Geny; Noia, Vincenzo Di; D'Argento, Ettore; Vita, Emanuele; Ferrara, Miriam |
|
Nov 30, 2019 |
6998 |
| Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages. |
Lu, Di; Ni, Zhen; Liu, Xiguang; Feng, Siyang; Dong, Xiaoying; Shi, Xiaoshun; Zhai, Jianxue; Mai, Shi |
|
Nov 30, 2019 |
5370 |
| The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature. |
Tsiouprou, Ioanna; Zaharias, Athanasios; Spyratos, Dionisios |
|
Nov 30, 2019 |
5174 |
| Roche reports positive results from phase three Tecentriq trial in combination with Avastin. |
|
|
Nov 26, 2019 |
162 |
| Roche reports positive results from phase three Tecentriq trial in combination with Avastin. |
|
|
Nov 26, 2019 |
158 |
| Henaelwths. |
|
|
Nov 17, 2019 |
381 |
| CHMP recommends conditional EU approval of Roche's Polivy for people with previously treated aggressive lymphoma. |
|
|
Nov 15, 2019 |
1494 |
| Breast and kidney cancer drugs get approval for use across Scotland's NHS. |
|
|
Nov 11, 2019 |
373 |
| Global Neuroendocrine Tumors (NETs) Market Insights, Epidemiology and Market Forecasts, 2017-2018 & 2019-2028. |
|
|
Nov 7, 2019 |
1126 |
| Exelixis reports Q3 adjusted EPS 34c, consensus 19c. |
|
Financial report |
Oct 30, 2019 |
107 |
| Seattle Genetics (NASDAQ: SGEN). |
|
|
Oct 30, 2019 |
1843 |
| Global Small Cell Lung Cancer Pipeline Report 2019: Diverse First-in-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease. |
|
Report |
Oct 29, 2019 |
864 |
| FDA Labeling Restriction Quickly Reflected in Oncology Practice; FDA label change linked to decrease in immunotherapy use, increases in chemotherapy use, PD-L1 testing. |
|
|
Oct 29, 2019 |
327 |
| Chugai Pharmaceutical Co., Ltd. - Tecentriq in Combination with Avastin Increases Overall Survival and Progression-free Survival as an Initial Treatment in People with Unresectable Hepatocellular Carcinoma -- 21/10/2019. |
|
|
Oct 22, 2019 |
241 |
| Bavarian Nordic provides update on stage 1 of phase 2 study of CV301 in bladder cancer. |
|
|
Oct 21, 2019 |
353 |
| Roche's Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma. |
|
|
Oct 21, 2019 |
1465 |
| Bavarian Nordic provides update on stage 1 of phase 2 study of CV301 in bladder cancer. |
|
|
Oct 21, 2019 |
354 |
| Bavarian Nordic provides update on stage 1 of phase 2 study of CV301 in bladder cancer. |
|
|
Oct 21, 2019 |
349 |
| Seattle Genetics (NASDAQ: SGEN). |
|
|
Oct 17, 2019 |
1994 |
| Seattle Genetics (NASDAQ: SGEN). |
|
|
Oct 9, 2019 |
1805 |
| China's drug watchdog grants approval to I-Mab Biopharma's IND application for TJD5. |
|
|
Oct 7, 2019 |
250 |
| China's drug watchdog grants approval to I-Mab Biopharma's IND application for TJD5. |
|
|
Oct 7, 2019 |
246 |
| NHS denied use of cancer drug; UK & WORLD. |
|
|
Oct 3, 2019 |
147 |
| NHS denied use of cancer drug; UK & WORLD. |
|
|
Oct 3, 2019 |
147 |
| Roche Products UK - Roche presents positive Phase III results for Tecentriq[R] (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer -- 30/9/2019. |
|
|
Oct 2, 2019 |
419 |
| Seattle Genetics (NASDAQ: SGEN). |
|
|
Oct 2, 2019 |
1843 |
| Genentech (SIX: RO, ROG; OTCQX: RHHBY) - Genentech Presents Positive Phase III Results for Tecentriq (Atezolizumab) in Combination With Platinum-Based Chemotherapy in People With Previously Untreated Advanced Bladder Cancer -- 30/9/2019. |
|
|
Oct 1, 2019 |
579 |
| BeyondSpring presents trial design for DUBLIN-3 study BPI-2358-103. |
|
|
Oct 1, 2019 |
344 |
| Lichenoid dermatitis with checkpoint inhibitor use described. |
Nogrady, Bianca |
|
Oct 1, 2019 |
472 |
| Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients. |
Duffy, Michael J.; Crown, John |
|
Oct 1, 2019 |
8376 |
| Roche presents positive Phase III results for Tecentriq® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer. |
|
|
Sep 30, 2019 |
1469 |
| Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors. |
Schepisi, Giuseppe; Brighi, Nicole; Cursano, Maria Concetta; Gurioli, Giorgia; Ravaglia, Giorgia; Al |
|
Sep 30, 2019 |
8889 |
| Invasive Aspergillosis in a Patient with Stage III (or 3a or 3b) Non-Small-Cell Lung Cancer Treated with Durvalumab. |
Gupta, Ashish; Tun, Aung; Ticona, Katy; Baqui, Aam; Guevara, Elizabeth |
|
Sep 30, 2019 |
2150 |
| Immunomedics presents interim data from TROPHY-U-01 open-label Phase 2 trial. |
|
|
Sep 29, 2019 |
296 |
| Roche's Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma. |
|
|
Sep 27, 2019 |
1919 |
| Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer. |
|
|
Sep 27, 2019 |
1411 |
| Seattle Genetics (NASDAQ: SGEN). |
|
|
Sep 25, 2019 |
1844 |
| Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress. |
|
|
Sep 23, 2019 |
1237 |
| Seattle Genetics (NASDAQ: SGEN). |
|
|
Sep 19, 2019 |
1806 |
| Roche's Tecentriq improves overall survival rate in IMpower110 study. |
|
|
Sep 13, 2019 |
201 |
| Roche's Tecentriq improves overall survival rate in IMpower110 study. |
|
|
Sep 13, 2019 |
197 |
| Roche's Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy. |
|
|
Sep 12, 2019 |
1277 |
| Roche (Philippines) Inc. Immunotherapy treatment available for advanced Metastatic Bladder Cancer. |
|
|
Sep 6, 2019 |
751 |
| European Commission approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer. |
|
|
Sep 6, 2019 |
1496 |
| European Commission approves Roche's new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer. |
|
|
Sep 6, 2019 |
333 |
| Roche Gets Thumbs Up In Europe To Expand Lung Cancer Drug. |
|
|
Sep 6, 2019 |
163 |
| Global Immune Checkpoint Inhibitors Market Report, 2019-2022 - Opdivo & Keytruda Presents Significant Growth Opportunity. |
|
Report |
Sep 5, 2019 |
826 |
| What the Oncologist Needs From the Pathologist for Tyrosine Kinase Inhibitor Therapies. |
Bernicker, Eric H. |
|
Sep 1, 2019 |
3752 |
| Seattle Genetics (NASDAQ: SGEN). |
|
|
Aug 29, 2019 |
1805 |
| European Commission approves Roche's Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer. |
|
|
Aug 29, 2019 |
366 |
| Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq. |
|
|
Aug 29, 2019 |
1290 |
| Chugai Pharmaceutical Co., Ltd. - Tecentriq, an Anti-PD-L1 Antibody, Receives Approval for Additional Indication of Extensive-Stage Small Cell Lung Cancer -- 22/8/2019. |
|
|
Aug 27, 2019 |
727 |
| Non-Small Cell Lung Cancer Market Huge Growth Opportunities and Challenges to Watch in 2019. |
|
|
Aug 22, 2019 |
950 |
| Seattle Genetics (NASDAQ: SGEN). |
|
|
Aug 20, 2019 |
1806 |
| Seattle Genetics (NASDAQ: SGEN). |
|
|
Aug 13, 2019 |
1806 |
| Genentech (SIX: RO, ROG; OTCQX: RHHBY) - Genentech's Tecentriq[R] (Atezolizumab) Plus Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death in People With Previously Untreated Advanced Bladder Cancer -- 4/8/2019. |
|
|
Aug 13, 2019 |
456 |
| Genentech's Tecentriq Plus Platinum-based Chemotherapy Reduced the Risk of Disease Worsening or Death in People with Previously Untreated Advanced Bladder Cancer. |
|
|
Aug 6, 2019 |
577 |
| Genentech (SIX: RO, ROG; OTCQX: RHHBY) - Genentech's Tecentriq[R] (Atezolizumab) Plus Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death in People With Previously Untreated Advanced Bladder Cancer -- 4/8/2019. |
|
|
Aug 6, 2019 |
456 |
| Roche's Tecentriq plus platinum-based chemotherapy reduced the risk of disease worsening or death in people with previously untreated advanced bladder cancer. |
|
|
Aug 5, 2019 |
1208 |
| Foundation Medicine Names Priti Hegde, Ph.D., as Chief Scientific Officer; Renowned oncology leader to head scientific innovation at Foundation Medicine. |
|
|
Aug 5, 2019 |
561 |
| Genentech says Phase III IMvigor130 study met co-primary endpoint. |
|
|
Aug 5, 2019 |
201 |
| Seattle Genetics (NASDAQ: SGEN). |
|
|
Jul 31, 2019 |
1808 |
| Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer. |
Bari, Shahla; Muzaffar, Jameel; Chan, Austin; Jain, Sanjay R.; Haider, Ahmad M.; Curry, Marjorie Ada |
|
Jul 31, 2019 |
3346 |
| DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy. |
Gilmore, Elaine; McCabe, Nuala; Kennedy, Richard D.; Parkes, Eileen E. |
|
Jul 31, 2019 |
10417 |
| European Medicines Agency committee grants positive opinion to Roche's Tecentriq (atezolizumab) and chemotherapy combination. |
|
|
Jul 30, 2019 |
184 |
| European Medicines Agency committee grants positive opinion to Roche's Tecentriq (atezolizumab) and chemotherapy combination. |
|
|
Jul 30, 2019 |
180 |
| CHMP recommends EU approval of Roche's Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer. |
|
|
Jul 26, 2019 |
1395 |
| Roche receives CHMP positive opinion for new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer. |
|
|
Jul 26, 2019 |
268 |
| Celgene Corporation (NASDAQ: CELG). |
|
|
Jul 25, 2019 |
1875 |
| Seattle Genetics (NASDAQ: SGEN). |
|
|
Jul 25, 2019 |
1844 |
| Celgene Corporation (NASDAQ: CELG). |
|
|
Jul 17, 2019 |
1925 |
| Seattle Genetics (NASDAQ: SGEN). |
|
|
Jul 17, 2019 |
1844 |
| Exelixis Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors. |
|
|
Jul 16, 2019 |
1007 |
| Exelixis expands COSMIC-021 study, adds four new cohorts. |
|
|
Jul 15, 2019 |
634 |
| Celgene Corporation (NASDAQ: CELG). |
|
|
Jul 9, 2019 |
1875 |
| Celgene Corporation (NASDAQ: CELG). |
|
|
Jul 4, 2019 |
1924 |
| European Medicines Agency's Committee for Medicinal Products for Human Use recommends approval of Roche's Tecentriq plus Abraxane. |
|
|
Jul 2, 2019 |
156 |
| European Medicines Agency's Committee for Medicinal Products for Human Use recommends approval of Roche's Tecentriq plus Abraxane. |
|
|
Jul 2, 2019 |
152 |
| SHOW CLINICAL SPOTLIGHTS. |
|
|
Jul 1, 2019 |
1155 |
| Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC). |
Sheng, Iris Y.; Kruse, Megan; Leininger, Kathryn M.; Ornstein, Moshe C. |
Report |
Jun 30, 2019 |
882 |
| Celgene Corporation (NASDAQ: CELG). |
|
|
Jun 25, 2019 |
1921 |
| Celgene Corporation (NASDAQ: CELG). |
|
|
Jun 18, 2019 |
1924 |
| Celgene Corporation (NASDAQ: CELG). |
|
|
Jun 13, 2019 |
1881 |
| Ipsen - New investigational clinical data for Ipsen's oncology products in 11 solid tumor types to be presented at 2019 ASCO Annual Meeting - 24/5/2019. |
|
|
Jun 13, 2019 |
342 |
| Ipsen - New investigational clinical data for Ipsen's oncology products in 11 solid tumor types to be presented at 2019 ASCO Annual Meeting - 24/5/2019. |
|
|
Jun 5, 2019 |
341 |
| The Prevalence of Systemic Rheumatic Diseases Among Breast Cancer Patients and Its Relationship With Survival. |
Sunar, Veli; Ates, Ozturk; Aslan, Alma Korcali; Karakas, Yusuf; Altundag, Mustafa Kadri |
|
Jun 1, 2019 |
3961 |
| Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma. |
Zajac, Magdalena; Boothman, Anne-Marie; Ben, Yong; Gupta, Ashok; Jin, Xiaoping; Mistry, Amita; Sabal |
|
Jun 1, 2019 |
8492 |
| The ADC Market is Fast Evolving: Applications of ADCs are widening and improvements in the manufacturing process meet industry requirements. |
Johnson, Charlie |
|
Jun 1, 2019 |
1867 |
| Immunotherapy in Prostate Cancer. |
Bolat, Deniz; Haydaroglu, Ayfer |
|
Jun 1, 2019 |
4730 |
| Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naive Vision of a Single Biomarker. |
Signorelli, Diego; Giannatempo, Patrizia; Grazia, Giulia; Aiello, Marco Maria; Bertolini, Federica; |
|
May 31, 2019 |
11914 |
| Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis. |
Zhang, Leyin; Sun, Leitao; Yu, Jieru; Shan, Feiyu; Zhang, Kai; Pang, Xi; Ma, Chenghao; Zhang, Yinan; |
|
May 31, 2019 |
9612 |
| Celgene Corporation (NASDAQ: CELG). |
|
|
May 29, 2019 |
1881 |
| Seattle Genetics Appoints Taylor as Chief Commercial Officer. |
|
|
May 24, 2019 |
383 |
| Synlogic Forges Clinical Collaboration to Evaluate SYNB1891 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors. |
|
|
May 24, 2019 |
538 |
| Celgene Corporation (NASDAQ: CELG). |
|
|
May 22, 2019 |
1924 |
| Synlogic, Roche announce collaboration to explore SYNB1891 with atezolizumab. |
|
|
May 22, 2019 |
309 |
| Celgene Corporation (NASDAQ: CELG). |
|
|
May 15, 2019 |
1883 |
| Pieris Pharmaceuticals reports Q1 EPS (20c), consensus (18c). |
|
Financial report |
May 10, 2019 |
186 |
| Celgene Corporation (NASDAQ: CELG). |
|
|
May 9, 2019 |
1878 |
| Celgene Corporation (NASDAQ: CELG). |
|
|
May 2, 2019 |
1920 |
| Current Status of Immunotherapy for Localized and Locally Advanced Renal Cell Carcinoma. |
Ghali, Fady; Patel, Sunil H.; Derweesh, Ithaar H. |
|
Apr 30, 2019 |
5953 |
| The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience. |
Vigliar, Elena; Malapelle, Umberto; Bono, Francesca; Fusco, Nicola; Cortinovis, Diego; Valtorta, Ema |
|
Apr 30, 2019 |
3972 |
| Forty Seven expands agreement with Genentech for third 5F9 with rituximab trial. |
|
|
Apr 26, 2019 |
146 |
| Celgene Corporation (NASDAQ: CELG). |
|
|
Apr 25, 2019 |
1700 |
| Celgene Corporation (NASDAQ: CELG). |
|
|
Apr 16, 2019 |
1699 |
| Celgene Corporation (NASDAQ: CELG). |
|
|
Apr 11, 2019 |
1742 |
| I-Mab Biopharma partners with Roche for atezolizumab & TJD5 combination therapy study. |
|
|
Apr 11, 2019 |
153 |
| I-Mab Biopharma partners with Roche for atezolizumab & TJD5 combination therapy study. |
|
|
Apr 11, 2019 |
149 |
| Tesetaxel Brain Concentrations Exceeded Concentrations Required for Tumor Killing for Sustained Period of Time in Preclinical Testing, According to Odonate Therapeutics. |
|
|
Apr 4, 2019 |
951 |
| Odonate Therapeutics Initiates CONTESSA TRIO Phase 2 Study of Tesetaxel. |
|
|
Apr 1, 2019 |
731 |
| Espoir dans le traitement du cancer : l'immunotherapie. |
|
|
Mar 29, 2019 |
777 |
| FDA Approves Genentech's Tecentriq in Combination with Chemotherapy for the Initial Treatment of Adults with Extensive-Stage Small Cell Lung Cancer. |
|
|
Mar 21, 2019 |
390 |
| CSI Laboratories Begins offering Ventana PD-L1 (SP142) Assay as Companion Diagnostic Test for Triple Negative Breast Cancer as a Result of FDA Approval for Tencentriq. |
|
|
Mar 20, 2019 |
257 |
| Roche's Tecentriq chemotherapy combination granted FDA approval for the initial treatment of adults with extensive-stage small cell lung cancer. |
|
|
Mar 19, 2019 |
293 |
| Roche's Tecentriq chemotherapy combination granted FDA approval for the initial treatment of adults with extensive-stage small cell lung cancer. |
|
|
Mar 19, 2019 |
289 |
| Celgene Provides Update on Abraxane Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer. |
|
|
Mar 14, 2019 |
668 |
| EC approves marketing authorisation for Roche's Tecentriq in combination with Avastin and chemotherapy. |
|
|
Mar 12, 2019 |
252 |
| EC approves marketing authorisation for Roche's Tecentriq in combination with Avastin and chemotherapy. |
|
|
Mar 12, 2019 |
248 |
| Systemic Therapy in Metastatic Castration-Resistant Prostate Cancer/Metastatik Kastrasyona Direncli Prostat Kanserinde Sistemik Tedavi. |
Dulgar, Ozgecan; Yilmaz, Mesut; Tural, Deniz |
|
Nov 1, 2018 |
2940 |
| Chemoimmunotherapy Ups Survival in Triple-Negative Breast Cancer; Atezolizumab plus nab-paclitaxel prolongs progression-free survival in metastatic disease. |
|
|
Oct 22, 2018 |
298 |
| PD-L1 Expression and [CD8.sup.+] T Cell Infiltration Predict a Favorable Prognosis in Advanced Gastric Cancer. |
Wang, Yangyang; Zhu, Chunchao; Song, Wei; Li, Jun; Zhao, Gang; Cao, Hui |
|
Jan 1, 2018 |
5581 |
| Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis. |
Su, Qiang; Zhang, Xiao-chen; Zhang, Chen-guang; Hou, Yan-li; Yao, Yu-xia; Cao, Bang-wei |
|
Jan 1, 2018 |
5793 |
| Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. |
Sui, Hongshu; Ma, Ningxia; Wang, Ying; Li, Hui; Liu, Xiaoming; Su, Yanping; Yang, Jiali |
Clinical report |
Jan 1, 2018 |
12468 |
| The Application of Nanoparticle-Based Drug Delivery Systems in Checkpoint Blockade Cancer Immunotherapy. |
Zhao, Huan; Li, Yuanqi; Wei, Dan; Luo, Hongrong |
|
Jan 1, 2018 |
6860 |
| Combination Immunotherapy Approaches for Pancreatic Cancer Treatment. |
Cheng, Xianliang; Zhao, Gang; Zhao, Yunqi |
|
Jan 1, 2018 |
5627 |
| A Complex Cardiac Mass Originating from Interatrial Septum in a Patient with History of Kidney Cancer: A Case Report and Literature Review. |
Faramarzi, Negar; Sohal, Sumit; Habibi, Roshanak; Akbar, Muhammad Sikander |
|
Jan 1, 2018 |
1547 |
| A Rare Presentation of Cardiac Tamponade from Metastatic Urothelial Carcinoma of the Bladder. |
Palam, Sowmya; Kapoor, Ridhima; Kulinski, Jacquelyn |
|
Jan 1, 2018 |
1815 |
| Transforming of the Tumor Microenvironment: Implications for TGF-[beta] Inhibition in the Context of Immune-Checkpoint Therapy. |
Loffek, Stefanie |
|
Jan 1, 2018 |
6917 |
| Update on the Treatment of Metastatic Urothelial Carcinoma. |
Bukhari, Nedal; Al-Shamsi, Humaid O.; Azam, Faisal |
Clinical report |
Jan 1, 2018 |
5209 |
| Precision Medicine for Breast Cancer: The Paths to Truly Individualized Diagnosis and Treatment. |
Harris, Eleanor E.R. |
Report |
Jan 1, 2018 |
6464 |
| Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer. |
D'Ascanio, Michela; Pezzuto, Aldo; Fiorentino, Chiara; Sposato, Bruno; Bruno, Pierdonato; Grieco, Al |
|
Jan 1, 2018 |
4042 |
| Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials. |
Zhao, Qiuling; Xie, Ruixiang; Lin, Shen; You, Xiang; Weng, Xiuhua |
|
Jan 1, 2018 |
5282 |
